This is where Design to Value intersects with digital.. For master planning, this is an approach that is proven to deliver substantial benefit to clients, against a wide range of value drivers.

“But we should be able to show them there's something better.”.The owners want all of this, but the general contractors tell them it isn’t possible.

They can’t tell them the concrete steps of action after the vision.They should figure out how to get those owners what they want, Marks says, and the owners need to be willing to take on some risk.They need to collaborate.

“Just because you push risk onto somebody else doesn't make risk go away.We have to start opening up our eyes and stop pushing down responsibility onto somebody else.

That's why we're so siloed.

Also, we can't keep automating inefficient processes.”.Professor John Dyson spent more than 25 years at GlaxoSmithKline, eventually ending his career as VP, Head of Capital Strategy and Design, where he focussed on developing a long-term strategic approach to asset management..

While there, he engaged Bryden Wood and together they developed the Front End Factory, a collaborative endeavour to explore how to turn purpose and strategy into the right projects – which paved the way for Design to Value.He is committed to the betterment of lives through individual and collective endeavours.. As well as his business and pharmaceutical experience, Dyson is Professor of Human Enterprise at the University of Birmingham, focussing on project management, business strategy and collaboration.. Additionally, he is a qualified counsellor with a private practice and looks to bring the understanding of human behaviour into business and projects.. To learn more about our Design to Value philosophy, read Design to Value: The architecture of holistic design and creative technology by Professor John Dyson, Mark Bryden, Jaimie Johnston MBE and Martin Wood.

Available to purchase at.'Transforming Small Molecule API Manufacturing' explores the innovative strides being made towards more efficient, sustainable, and cost-effective drug production.. Adrian La Porta.shares his insights on the pivotal role of miniaturisation and automation in shaping the future of Active Pharmaceutical Ingredients (APIs) production, highlighting the potential for significant industry transformation.. Watch now for a unique perspective on how modern advancements are paving the way for a new era in pharmaceuticals, not only redefining manufacturing processes but also promising a healthier future for all.Presented by our Head of Sustainability, Helen Hough, this video takes you on a journey through the development of The Forge, a landmark London project that represents a significant leap in sustainable construction..